What is VivoSim Labs Inc's earnings per share (EPS)?

VivoSim Labs Inc (VIVS) reported diluted earnings per share of $-1.70 for fiscal year 2025. This represents a 91.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

VivoSim Labs Inc Financials

VIVS

Source SEC Filings (10-K/10-Q) Data as of Dec 31, 2025 Currency USD FYE March

This page shows VivoSim Labs Inc (VIVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VIVS FY2025 2026-07-14

External cash replenishment, not commercial scale, is the dominant mechanic as operating burn continues to fund the business

FY2025’s net-loss improvement to $2.5M from $14.7M looks stronger than the operating reality. Operating cash outflow still ran at nearly $9.5M, so the earnings recovery did not translate into a comparable reduction in the cash cost of running the business.

Near-term liquidity looks serviceable because cash ended FY2025 at $11.3M against current liabilities of $3.7M, roughly a 3.2x current coverage. But that cushion was rebuilt externally: financing added $8.8M and investing produced $9.0M, while operations still consumed cash. The asset base more than doubled from FY2024 in a single year without operating self-funding.

With revenue only $144K, this is still a development-stage cost structure rather than a scaled operating model. Expense restraint matters more than sales here: SG&A alone was $7.7M, so the smaller operating loss reflects cost reduction more than commercial traction. R&D also exceeded revenue, so the company is still funding development rather than harvesting demand.

Financial Health Signals

Financial health score pending refresh

We are recalculating VivoSim Labs Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Altman Z-Score Distress

-34.50

VivoSim Labs Inc scores -34.50, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.3M) relative to total liabilities ($4.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/7

VivoSim Labs Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

3.80x

For every $1 of reported earnings, VivoSim Labs Inc generates $3.80 in operating cash flow (-$9.5M OCF vs -$2.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-1261.6x

VivoSim Labs Inc earns $-1261.6 in operating income for every $1 of interest expense (-$12.6M vs $10K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$144K

YoY+32.1%

5Y CAGR-42.0%

10Y CAGR-12.9%

VivoSim Labs Inc generated $144K in revenue in fiscal year 2025. This represents an increase of 32.1% from the prior year.

EBITDA

-$12.3M

YoY+16.6%

VivoSim Labs Inc's EBITDA was -$12.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.6% from the prior year.

Net Income

-$2.5M

YoY+83.0%

VivoSim Labs Inc reported -$2.5M in net income in fiscal year 2025. This represents an increase of 83.0% from the prior year.

EPS (Diluted)

$-1.70

YoY+91.2%

VivoSim Labs Inc earned $-1.70 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$9.5M

YoY+35.5%

VivoSim Labs Inc generated -$9.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 35.5% from the prior year.

Cash & Debt

$11.3M

YoY+289.9%

5Y CAGR-16.2%

10Y CAGR-13.8%

VivoSim Labs Inc held $11.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+126.0%

VivoSim Labs Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 126.0% from the prior year.

Margins & Returns

Gross Margin

96.5%

5Y CAGR+11.5pp

10Y CAGR-3.5pp

VivoSim Labs Inc's gross margin was 96.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.

Operating Margin

-8761.1%

YoY+5079.3pp

5Y CAGR-7783.2pp

10Y CAGR-3455.2pp

VivoSim Labs Inc's operating margin was -8761.1% in fiscal year 2025, reflecting core business profitability. This is up 5079.3 percentage points from the prior year.

Net Margin

-1727.8%

YoY+11731.9pp

5Y CAGR-875.8pp

10Y CAGR+3540.5pp

VivoSim Labs Inc's net profit margin was -1727.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11731.9 percentage points from the prior year.

Return on Equity

-23.7%

YoY+383.7pp

5Y CAGR+46.6pp

10Y CAGR+38.1pp

VivoSim Labs Inc's ROE was -23.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 383.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$5.0M

YoY-8.6%

5Y CAGR-1.0%

10Y CAGR-9.0%

VivoSim Labs Inc invested $5.0M in research and development in fiscal year 2025. This represents a decrease of 8.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$13K

YoY-69.0%

10Y CAGR-37.9%

VivoSim Labs Inc invested $13K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 69.0% from the prior year.

VIVS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$144K+32.1%	$109K-70.5%	$370K-75.3%	$1.5M	$0-100.0%	$2.2M
Cost of Revenue	$5K	N/A	N/A	N/A	$0-100.0%	$328K
Gross Profit	$139K	N/A	N/A	N/A	$0-100.0%	$1.9M
R&D Expenses	$5.0M-8.6%	$5.5M-38.1%	$8.9M+167.6%	$3.3M+201.0%	$1.1M-79.1%	$5.3M
SG&A Expenses	$7.7M-20.3%	$9.7M+5.2%	$9.2M-4.6%	$9.7M-38.6%	$15.7M-12.9%	$18.1M
Operating Income	-$12.6M+16.4%	-$15.1M+14.9%	-$17.7M-54.5%	-$11.5M+31.8%	-$16.8M+21.6%	-$21.5M
Interest Expense	$10K	N/A	N/A	N/A	N/A	N/A
Income Tax	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K0.0%	$2K
Net Income	-$2.5M+83.0%	-$14.7M+15.0%	-$17.3M-50.8%	-$11.4M+32.0%	-$16.8M+10.1%	-$18.7M
EPS (Diluted)	$-1.70+91.2%	$-19.25-872.2%	$-1.98-50.0%	$-1.32	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$26K-7.1%	$28K-24.3%	$37K-27.5%	$51K+112.5%	$24K-20.0%	$30K-23.1%	$39K	N/A
Cost of Revenue	$0	$0	$0	$0-100.0%	$2K+100.0%	$1K-50.0%	$2K	N/A
Gross Profit	$26K-7.1%	$28K-24.3%	$37K-27.5%	$51K+131.8%	$22K-24.1%	$29K-21.6%	$37K	N/A
R&D Expenses	$1.1M+23.5%	$923K-7.8%	$1.0M+16.5%	$859K-51.7%	$1.8M+80.9%	$984K-29.8%	$1.4M	N/A
SG&A Expenses	$1.6M-6.0%	$1.7M-10.8%	$2.0M-16.8%	$2.3M+37.2%	$1.7M+3.4%	$1.7M-18.2%	$2.0M	N/A
Operating Income	-$2.8M-4.4%	-$2.6M+9.6%	-$2.9M+7.6%	-$3.2M+9.1%	-$3.5M-33.0%	-$2.6M+23.0%	-$3.4M	N/A
Interest Expense	$4K	$0-100.0%	$4K-20.0%	$5K0.0%	$5K	$0	$0	N/A
Income Tax	$0-100.0%	$2K	$0	$0	$0	$0-100.0%	$2K	N/A
Net Income	-$2.7M-5.7%	-$2.5M+10.5%	-$2.8M-141.5%	$6.9M+298.8%	-$3.4M-35.2%	-$2.5M+23.8%	-$3.3M	N/A
EPS (Diluted)	$-1.03-5.1%	$-0.98+14.0%	$-1.14	N/A	$-2.28-35.7%	$-1.68+38.7%	$-2.74	N/A

VIVS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$14.7M+130.7%	$6.3M-68.7%	$20.3M-39.0%	$33.3M-16.6%	$39.9M+40.4%	$28.4M
Current Assets	$12.1M+208.2%	$3.9M-76.9%	$17.0M-42.3%	$29.5M-23.1%	$38.4M+35.6%	$28.3M
Cash & Equivalents	$11.3M+289.9%	$2.9M-81.0%	$15.3M-46.6%	$28.7M-23.3%	$37.4M+36.6%	$27.4M
Inventory	$0-100.0%	$297K	$0	N/A	N/A	$0
Accounts Receivable	$30K-9.1%	$33K-78.3%	$152K	$0	$0-100.0%	$111K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.2M+51.3%	$2.7M-44.9%	$5.0M+61.5%	$3.1M+328.2%	$721K-60.2%	$1.8M
Current Liabilities	$3.7M+100.9%	$1.9M-49.3%	$3.7M+165.4%	$1.4M+91.8%	$721K-60.2%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$10.5M+191.4%	$3.6M-76.5%	$15.3M-49.3%	$30.2M-22.9%	$39.2M+47.2%	$26.6M
Retained Earnings	-$342.2M-0.7%	-$339.7M-4.5%	-$325.0M-5.6%	-$307.7M-3.9%	-$296.3M-6.0%	-$279.5M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$7.0M-28.1%	$9.7M-19.1%	$12.0M-18.2%	$14.7M+281.1%	$3.8M-43.1%	$6.8M-28.7%	$9.5M+49.2%	$6.3M
Current Assets	$6.0M-20.4%	$7.6M-21.6%	$9.7M-20.2%	$12.1M+477.7%	$2.1M-56.1%	$4.8M-34.3%	$7.3M+85.0%	$3.9M
Cash & Equivalents	$4.3M-35.8%	$6.7M-26.3%	$9.1M-20.0%	$11.3M+874.3%	$1.2M-63.4%	$3.2M-48.7%	$6.2M+113.3%	$2.9M
Inventory	N/A	N/A	N/A	$0	$0-100.0%	$640K+56.9%	$408K+37.4%	$297K
Accounts Receivable	$33K+3.1%	$32K0.0%	$32K+6.7%	$30K+15.4%	$26K-10.3%	$29K-39.6%	$48K+45.5%	$33K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.5M-3.9%	$2.6M+7.4%	$2.4M-41.3%	$4.2M+19.5%	$3.5M+13.2%	$3.1M+9.5%	$2.8M+2.2%	$2.7M
Current Liabilities	$2.5M+1.1%	$2.4M+14.3%	$2.1M-42.7%	$3.7M+27.2%	$2.9M+21.7%	$2.4M+18.7%	$2.0M+9.3%	$1.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.4M-37.1%	$7.1M-25.9%	$9.5M-9.1%	$10.5M+2782.4%	$364K-90.1%	$3.7M-44.8%	$6.7M+85.0%	$3.6M
Retained Earnings	-$350.2M-0.8%	-$347.5M-0.7%	-$345.0M-0.8%	-$342.2M+2.0%	-$349.0M-1.0%	-$345.6M-0.7%	-$343.0M-1.0%	-$339.7M

VIVS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.5M+35.4%	-$14.7M-18.1%	-$12.4M-46.8%	-$8.5M+36.6%	-$13.3M+10.5%	-$14.9M
Capital Expenditures	$13K-69.0%	$42K-89.4%	$396K-3.2%	$409K+1.0%	$405K	$0
Free Cash Flow	-$9.5M+35.5%	-$14.7M-14.8%	-$12.8M-44.5%	-$8.9M+35.4%	-$13.7M+7.8%	-$14.9M
Investing Cash Flow	$9.0M+1006.0%	$816K+184.5%	-$966K-136.2%	-$409K-4.1%	-$393K-152.6%	$747K
Financing Cash Flow	$8.8M+515.7%	$1.4M	$0-100.0%	$205K-99.1%	$23.8M+383.0%	$4.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0-100.0%	$1K	$0

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$2.3M+4.5%	-$2.4M+39.6%	-$3.9M-93.6%	-$2.0M-13.0%	-$1.8M+31.8%	-$2.6M+11.4%	-$3.0M-11.7%	-$2.7M
Capital Expenditures	$0	N/A	N/A	$0	$0-100.0%	$13K	$0	$0
Free Cash Flow	-$2.3M	N/A	N/A	-$2.0M-13.0%	-$1.8M+32.2%	-$2.7M+11.0%	-$3.0M-11.7%	-$2.7M
Investing Cash Flow	$0	$0	$0-100.0%	$9.0M+224925.0%	$4K	$0-100.0%	$20K+53.8%	$13K
Financing Cash Flow	-$118K	$0-100.0%	$1.7M-47.2%	$3.2M+1574.5%	-$216K+41.8%	-$371K-105.9%	$6.2M+2267.0%	$264K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VIVS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	96.5%	N/A	N/A	N/A	N/A	85.1%
Operating Margin	-8761.1%+5079.3pp	-13840.4%-9048.2pp	-4792.2%-4026.9pp	-765.3%	N/A	-977.9%
Net Margin	-1727.8%+11731.9pp	-13459.6%-8795.0pp	-4664.6%-3901.4pp	-763.2%	N/A	-852.0%
Return on Equity	-23.7%+383.7pp	-407.4%-294.8pp	-112.6%-74.7pp	-37.9%+5.0pp	-42.9%+27.3pp	-70.3%
Return on Assets	-17.0%+214.1pp	-231.1%-146.1pp	-85.0%-50.6pp	-34.4%+7.8pp	-42.1%+23.6pp	-65.8%
Current Ratio	3.25+1.1	2.12-2.5	4.64-16.7	21.35-31.9	53.26+37.6	15.65
Debt-to-Equity	0.40-0.4	0.76+0.4	0.33+0.2	0.10+0.1	0.02-0.0	0.07
FCF Margin	-6579.2%+6902.5pp	-13481.6%-10021.1pp	-3460.5%-2869.7pp	-590.8%	N/A	-677.7%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	100.0%0.0pp	100.0%0.0pp	100.0%0.0pp	100.0%+8.3pp	91.7%-5.0pp	96.7%+1.8pp	94.9%	N/A
Operating Margin	-10576.9%-1166.2pp	-9410.7%-1532.3pp	-7878.4%-1694.1pp	-6184.3%+8265.7pp	-14450.0%-5756.7pp	-8693.3%-11.3pp	-8682.0%	N/A
Net Margin	-10350.0%-1260.7pp	-9089.3%-1405.5pp	-7683.8%-21119.1pp	13435.3%+27797.8pp	-14362.5%-5865.8pp	-8496.7%+77.7pp	-8574.4%	N/A
Return on Equity	-60.6%-24.6pp	-36.0%-6.2pp	-29.8%-95.1pp	65.3%+1012.3pp	-947.0%-877.7pp	-69.3%-19.1pp	-50.2%	N/A
Return on Assets	-38.7%-12.4pp	-26.3%-2.5pp	-23.7%-70.5pp	46.8%+136.4pp	-89.7%-51.9pp	-37.7%-2.4pp	-35.3%	N/A
Current Ratio	2.44-0.7	3.10-1.4	4.52+1.3	3.25+2.5	0.71-1.3	1.98-1.6	3.58+1.5	2.12
Debt-to-Equity	0.57+0.2	0.37+0.1	0.26-0.1	0.40-9.2	9.56+8.7	0.84+0.4	0.42-0.3	0.76
FCF Margin	-8734.6%	N/A	N/A	-3990.2%+3514.0pp	-7504.2%+1345.8pp	-8850.0%-1201.3pp	-7648.7%	N/A

Similar Companies

Matinas Biopharm MTNB

$3.1M

IMV

$9.8M

Essa Pharma EPIX

$9.5M

Processa Pharmaceuticals Inc PCSA

$5.7M

Cyclacel Phar Pr CYCCP

$9.6M

Frequently Asked Questions

What is VivoSim Labs Inc's annual revenue?

VivoSim Labs Inc (VIVS) reported $144K in total revenue for fiscal year 2025. This represents a 32.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is VivoSim Labs Inc's revenue growing?

VivoSim Labs Inc (VIVS) revenue grew by 32.1% year-over-year, from $109K to $144K in fiscal year 2025.

Is VivoSim Labs Inc profitable?

No, VivoSim Labs Inc (VIVS) reported a net income of -$2.5M in fiscal year 2025, with a net profit margin of -1727.8%.

What is VivoSim Labs Inc's EBITDA?

VivoSim Labs Inc (VIVS) had EBITDA of -$12.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is VivoSim Labs Inc's gross margin?

VivoSim Labs Inc (VIVS) had a gross margin of 96.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is VivoSim Labs Inc's operating margin?

VivoSim Labs Inc (VIVS) had an operating margin of -8761.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is VivoSim Labs Inc's net profit margin?

VivoSim Labs Inc (VIVS) had a net profit margin of -1727.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is VivoSim Labs Inc's return on equity (ROE)?

VivoSim Labs Inc (VIVS) has a return on equity of -23.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is VivoSim Labs Inc's free cash flow?

VivoSim Labs Inc (VIVS) generated -$9.5M in free cash flow during fiscal year 2025. This represents a 35.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is VivoSim Labs Inc's operating cash flow?

VivoSim Labs Inc (VIVS) generated -$9.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are VivoSim Labs Inc's total assets?

VivoSim Labs Inc (VIVS) had $14.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are VivoSim Labs Inc's capital expenditures?

VivoSim Labs Inc (VIVS) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does VivoSim Labs Inc spend on research and development?

VivoSim Labs Inc (VIVS) invested $5.0M in research and development during fiscal year 2025.

How many shares does VivoSim Labs Inc have outstanding?

VivoSim Labs Inc (VIVS) had 2M shares outstanding as of fiscal year 2025.

What is VivoSim Labs Inc's current ratio?

VivoSim Labs Inc (VIVS) had a current ratio of 3.25 as of fiscal year 2025, which is generally considered healthy.

What is VivoSim Labs Inc's debt-to-equity ratio?

VivoSim Labs Inc (VIVS) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is VivoSim Labs Inc's return on assets (ROA)?

VivoSim Labs Inc (VIVS) had a return on assets of -17.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is VivoSim Labs Inc's cash runway?

Based on fiscal year 2025 data, VivoSim Labs Inc (VIVS) had $11.3M in cash against an annual operating cash burn of $9.5M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is VivoSim Labs Inc's Altman Z-Score?

VivoSim Labs Inc (VIVS) has an Altman Z-Score of -34.50, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is VivoSim Labs Inc's Piotroski F-Score?

VivoSim Labs Inc (VIVS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are VivoSim Labs Inc's earnings high quality?

VivoSim Labs Inc (VIVS) has an earnings quality ratio of 3.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can VivoSim Labs Inc cover its interest payments?

VivoSim Labs Inc (VIVS) has an interest coverage ratio of -1261.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.